Human Genome Epidemiology Literature Finder
|
Records 1 - 18 (of 18 Records) |
| Query Trace: Disease Progression and CDK4[original query] |
|---|
| Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Mar . Vatrano Simona, Volante Marco, Duregon Eleonora, Giorcelli Jessica, Izzo Stefania, Rapa Ida, Votta Arianna, Germano Antonina, Scagliotti Giorgio, Berruti Alfredo, Terzolo Massimo, Papotti And Mau |
| Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct . Pearson Alex, Proszek Paula, Pascual Javier, Fribbens Charlotte, Shamsher Monee K, Kingston Belinda, O'Leary Ben, Herrera-Abreu Maria T, Cutts Rosalind J, Garcia-Murillas Isaac, Bye Hannah, Walker Brian A, Gonzalez De Castro David, Yuan Lina, Jamal Sabri, Hubank Mike, Lopez-Knowles Elena, Schuster Eugene F, Dowsett Mitch, Osin Peter, Nerurkar Ashutosh, Parton Marina, Okines Alicia F C, Johnston Stephen R D, Ring Alistair, Turner Nicholas |
| Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. Cancers 2020 8 12 (9): . Hilke Franz J, Sinnberg Tobias, Gschwind Axel, Niessner Heike, Demidov German, Amaral Teresa, Ossowski Stephan, Bonzheim Irina, Röcken Martin, Riess Olaf, Garbe Claus, Schroeder Christopher, Forschner Andr |
| Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer. Diagnostics (Basel, Switzerland) 2020 Jul 10 (8): . Niwinska Anna, Ba?abas Aneta, Kulecka Maria, Kluska Anna, Pi?tkowska Magdalena, Paziewska Agnieszka, Py?niak Kazimiera, Olszewski Wojciech, Mikula Micha?, Ostrowski Jer |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology 2021 4 22 (4): 489-498. Rugo Hope S, Lerebours Florence, Ciruelos Eva, Drullinsky Pamela, Ruiz-Borrego Manuel, Neven Patrick, Park Yeon Hee, Prat Aleix, Bachelot Thomas, Juric Dejan, Turner Nicholas, Sophos Nickolas, Zarate Juan Pablo, Arce Christina, Shen Yu-Ming, Turner Stuart, Kanakamedala Hemanth, Hsu Wei-Chun, Chia Steph |
| Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast cancer research : BCR 2021 Mar 23 (1): 31. Darrigues Lauren, Pierga Jean-Yves, Bernard-Tessier Alice, Bièche Ivan, Silveira Amanda Bartolini, Michel Marc, Loirat Delphine, Cottu Paul, Cabel Luc, Dubot Coraline, Geiss Romain, Ricci Francesco, Vincent-Salomon Anne, Proudhon Charlotte, Bidard François-Cléme |
| Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors. Oncology research and treatment 2022 2 45 (5): 248-253. Decker Thomas, Bichler Matthias, Birtel Andrea, Fischer Gerhard, Geiger Kathrin, Gaenger Stella, Nonnenbroich Christoph, Dechow Tobias, Muendlein Ax |
| Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer science 2022 2 113 (5): 1808-1820. Chin Yoon Ming, Shibayama Tomoko, Chan Hiu Ting, Otaki Masumi, Hara Fumikata, Kobayashi Takayuki, Kobayashi Kokoro, Hosonaga Mari, Fukada Ippei, Inagaki Lina, Ono Makiko, Ito Yoshinori, Takahashi Shunji, Ohno Shinji, Ueno Takayuki, Nakamura Yusuke, Low Siew-K |
| Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome medicine 2023 7 15 (1): 55. Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A Rejto, Woong-Yang Park, Zhengyan K |
| Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 OF1-OF7. Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Mill |
| Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England) 2023 4 . Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bida |
| Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 1 . Davis Andrew A, Luo Jingqin, Zheng Tiantian, Dai Chao, Dong Xiaoxi, Tan Lu, Suresh Rama, Ademuyiwa Foluso O, Rigden Caron, Rearden Timothy P, Clifton Katherine, Weilbaecher Katherine, Frith Ashley, Tandra Pavankumar K, Summa Tracy, Haas Brittney, Thomas Shana, Hernandez-Aya Leonel F, Peterson Lindsay L, Wang Xiaohong, Luo Shujun J, Zhou Kemin, Du Pan, Jia Shidong, King Bonnie L, Krishnamurthy Jairam, Ma Cynthia |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
| Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer. International journal of cancer 2024 8 . Charlotte K Kindt, Carla L Alves, Sidse Ehmsen, Amalie Kragh, Thomas Reinert, Marianne Vogsen, Annette R Kodahl, Jeanette D Rønlev, Dilan Ardik, Anna L Sørensen, Kirstine Evald, Mia L Clemmensen, Johan Staaf, Henrik J Ditz |
| Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis. Frontiers in oncology 2024 6 14 1408664. Marcin Kubeczko, Anna Polakiewicz-Gilowska, Katarzyna ?widerska, Aleksandra Le?niak, Marta Mianowska-Malec, Barbarba ?anoszka, Konstanty Chomik, Barbara Grandys, Natalya Lisovska, Barbara Bobek-Billewicz, Ewa Chmielik, Micha? Jarz |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet. Oncology 2024 12 25 (12): e629-e638. Hope S Rugo, Florence Lerebours, Eva Ciruelos, Pamela Drullinsky, Manuel Ruiz-Borrego, Patrick Neven, Yeon Hee Park, Aleix Prat, Thomas Bachelot, Dejan Juric, Nicholas Turner, Nickolas Sophos, Juan Pablo Zarate, Christina Arce, Yu-Ming Shen, Stuart Turner, Hemanth Kanakamedala, Wei-Chun Hsu, Stephen Ch |
| A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors. Biomedicines 2024 10 12 (10): . Alessandra Virga, Caterina Gianni, Michela Palleschi, Davide Angeli, Filippo Merloni, Roberta Maltoni, Paola Ulivi, Giovanni Martinelli, Ugo De Giorgi, Sara Bravacci |
| FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma. Contemporary oncology (Poznan, Poland) 2024 1 27 (3): 211-216. Julia Pikul, Anna Rzepakowska, Marcin Machnicki, Tomasz Stok?o |
- Page last reviewed:Feb 1, 2024
- Content source: